# OnCo record nct04079166 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04079166/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04079166", "NCT04079166" ;
  schema:name "SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)"@en ;
  schema:alternateName "SCOPE"@en ;
  schema:description "A phase 2 trial of SCIB1 or iSCIB1+ DNA vaccine in melanoma, run by Scancell Ltd, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04079166/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04079166> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2019-08-19" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:companies <https://onco.cc/companies/scancell/> .